Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
PALOMAR MEDICAL TECHNOLOGIES LLC (PMTI)
|
Add to portfolio |
|
|
|
| Price: |
$8.93
| | Metrics |
| OS: |
20.0
|
M
| |
1500
|
% ROE
|
| Market cap: |
$178
|
M
| |
2221
|
% ROIC
|
|
Net cash:
|
$101
|
M
| |
$5.05
|
per share
|
|
EV:
|
$77.6
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$3.7
|
B
| |
0.0
|
x EV/EBITDA
|
|
EBIT
|
$2.2
|
B
| |
0.0
|
x EV/EBIT
|
| EPS |
$119.78
| |
0.1
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| Revenues | 80.6 | 103.4 | 63.7 | 60.6 | 87.6 | 123.8 | 126.5 | 76.2 |
| Revenue growth | -22.1% | 62.3% | 5.2% | -30.8% | -29.3% | -2.2% | 66.2% | 39.9% |
| Cost of goods sold | 6.2 | 6.8 | 5.8 | 7.1 | 25.2 | 33.4 | 26.9 | 21.0 |
| Gross profit | 74.4 | 96.6 | 57.9 | 53.5 | 62.4 | 90.4 | 99.6 | 55.2 |
| Gross margin | 92.3% | 93.4% | 90.8% | 88.3% | 71.2% | 73.0% | 78.7% | 72.5% |
| Sales and marketing | 27.5 | 25.6 | 20.0 | 19.3 | 23.3 | 24.9 | 22.5 | 17.2 |
| Research and development | 10.3 | 15.6 | 15.5 | 14.7 | 17.7 | 16.7 | | |
| General and administrative | 10.9 | 8.7 | 14.5 | 11.3 | 20.5 | 17.5 | 7.6 | 7.9 |
| EBIT | -6.0 | 41.7 | -9.2 | -7.3 | -3.4 | 26.2 | 43.3 | 16.8 |
| EBIT margin | -7.4% | 40.4% | -14.4% | -12.1% | -3.9% | 21.1% | 34.2% | 22.0% |
| Pre-tax income | -5.7 | 11.5 | -8.5 | -6.0 | -0.1 | 33.1 | 48.0 | 17.9 |
| Income taxes | 0.5 | 4.1 | 0.3 | 4.4 | 0.0 | 12.6 | -5.0 | 0.5 |
| Tax rate | | 35.6% | | | | 38.0% | | 2.6% |
| Net income | -6.2 | 7.4 | -8.8 | -10.5 | -0.1 | 20.5 | 53.0 | 17.5 |
| Net margin | -7.7% | 7.2% | -13.8% | -17.3% | -0.1% | 16.6% | 41.9% | 22.9% |
| |
| Diluted EPS | ($0.33) | $0.39 | ($0.47) | ($0.58) | $0.00 | $1.07 | $2.62 | $0.91 |
| Shares outstanding (diluted) | 18.9 | 18.9 | 18.5 | 18.1 | 18.2 | 19.3 | 20.2 | 19.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|